title: New drugs and targeted treatments in Hodgkin's lymphoma.
abstract: New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
authors.affiliation: Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. Electronic address: mprovenciop@gmail.com.
authors.forename: Mariano
authors.initials: M
authors.lastname: Provencio
authors.affiliation: Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Sánchez
authors.affiliation: Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain.
authors.forename: Margarita
authors.initials: M
authors.lastname: Sánchez-Beato
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational
keywords: Bendamustine; Brentuximab vedotin; Deacetylase inhibitors; Hodgkin’s lymphoma; Lenalidomide; Target treatments; m-TOR inhibitors